Overview
CRST syndrome, not explicitly detailed in the provided abstracts, can be inferred to encompass characteristics often seen in overlap syndromes involving Raynaud's phenomenon, calcinosis, Raynaud's phenomenon, esophageal dysmotility, and scleroderma-like skin changes. However, the given abstracts focus primarily on Raynaud's syndrome in pediatric populations and its potential evolution into connective tissue diseases.Diagnosis
Perform anti-nuclear antibody (ANA) testing 1.
Consider testing for more specific antibodies associated with connective tissue diseases 1.
Conduct nail-fold capillaroscopy to assess microvascular changes 1.
Frequency of follow-up depends on presence of risk factors identified by initial tests 1.Management
No specific first-line treatments mentioned for CRST syndrome directly; focus on managing Raynaud's symptoms and monitoring for connective tissue disease evolution 1.
Adjunctive treatments may include vasodilators for symptomatic relief of Raynaud's phenomenon, though specific drug classes/doses are not detailed 1.Special Populations
Pediatrics: Testing for ANA, specific antibodies, and nail-fold capillaroscopy recommended in children with Raynaud's syndrome to identify risk of connective tissue disease progression 1.Key Recommendations
Test all pediatric patients with Raynaud's syndrome for anti-nuclear antibodies (ANA) and specific connective tissue disease antibodies (Evidence: Expert opinion) 1.
Perform nail-fold capillaroscopy in pediatric patients with Raynaud's syndrome to assess microvascular abnormalities (Evidence: Expert opinion) 1.
Tailor follow-up frequency based on initial test results, particularly focusing on high-risk individuals for early detection of evolving connective tissue disease (Evidence: Expert opinion) 1.References
1 Pain CE, Constantin T, Toplak N, Moll M, Iking-Konert C, Piotto DP et al.. Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clinical and experimental rheumatology 2016. link